دورية أكاديمية
Treating Patients with Aripiprazol: A Safe Gamble?
| العنوان: | Treating Patients with Aripiprazol: A Safe Gamble? |
|---|---|
| المؤلفون: | B. Leal, D. Vila-Chã, S. Garcia, I. Pinto, R. Mateiro, M. Avelino, M. Martins, J. Salgado |
| المصدر: | European Psychiatry, Vol 65, Pp S713-S713 (2022) |
| بيانات النشر: | Cambridge University Press, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Psychiatry |
| مصطلحات موضوعية: | Gambling Disorder, Aripiprazol, Dopamine receptor, Psychiatry, RC435-571 |
| الوصف: | Introduction Aripiprazole (ARI) is an atypical antipsychotic drug with D2 partial agonist properties, usually prescribed to treat mood disorders (major depression or bipolar disorder) and schizophrenic disorder (schizophrenia or schizoaffective disorder). Dopamine receptor agonists, as is ARI, have been implicated in some cases of impulse-control problems, such as gambling disorder (GD), increased spending, hypersexuality and compulsive eating. Objectives Currently, it is hypothesized that aripiprazole may cause impulse-control problems because it can produce a hyperdopaminergic state in the mesolimbic pathway (reward system) through its predominant action on dopamine D3 receptors. We intend to do a non-systematic review of the scientific information regarding this subject. Methods The authors revised the published literature about this topic, selecting relevant articles, systematic reviews and case reports, with the topic words: “aripiprazol”, “gambling disorder” and “dopamine receptor” in scientific data base. Results Overall, a few cases of ARI-induced pathological gambling as well as ARI-induced hypersexuality have been reported. In one study it was verified that comorbid psychiatric and substance use disorders were common among those who have experienced GD or worsened GD after beginning ARI treatment. In another study, it was verified that the group of patients who reported this alleged side-effect were mostly young (mean age, 33.6 years), mostly men (88.2%) and most lived alone. Conclusions Attributing to dopamine agonists the only factor that can explain the onset of GD is simplistic and dangerous. Many other potential risk factors, including individual vulnerability factors (temperament, genetics) as well as environmental factors, must be considered. Disclosure No significant relationships. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0924-9338 1778-3585 |
| Relation: | https://www.cambridge.org/core/product/identifier/S0924933822018387/type/journal_article; https://doaj.org/toc/0924-9338; https://doaj.org/toc/1778-3585 |
| DOI: | 10.1192/j.eurpsy.2022.1838 |
| URL الوصول: | https://doaj.org/article/119d5595db9146adbd58a15126c03ebd |
| رقم الأكسشن: | edsdoj.119d5595db9146adbd58a15126c03ebd |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 09249338 17783585 |
|---|---|
| DOI: | 10.1192/j.eurpsy.2022.1838 |